Lp(a) is more atherogenic than LDL-C, possibly because there is less clearance and more recycling of particles, and multiple guidelines now recommend Lp(a) measurement at least once in a lifetime, especially for those with a personal or family history of atherosclerotic cardiovascular disease. Dr Gissette Reyes-Soffer, Columbia University, New York, USA, discusses current understanding of Lp(a) atherogenicity and its relevance to primary and secondary prevention of cardiovascular disease.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.